ALZHEIMER'S DISEASE/MEMORY DISORDERS RESEARCH

Conversational Speech Analysis (CSA) Study (18-0456)

• Investigator: Peter Pressman, MD
• Purpose: to learn more about how speech changes over time in adult populations, understand how those changes reflect changes in cognition, and develop new ways of detecting MCI and dementia using everyday speech.
• Timeline: two study visits, one year apart.
• Study flyer: click here
• Key Eligibility Criteria: age: 40-95 years old, diagnosis: mild cognitive impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder.

ENVISION (22-0776)

• Investigator: Victoria Pelak, MD
• Purpose: to look at whether aducanumab (ADUHELM™, also known as BIIB037, the study drug) can help slow the development of AD symptoms in people with early AD.
• Intervention: BIIB037 (66% chance) or placebo (33% chance).
• Timeline: up to 39 in-person study visits over 130 weeks.
• Clinicaltrials.gov: NCT05310071 
• Key Eligibility Criteria: age: 60-85 years old, diagnosis: mild Alzheimer’s Disease (AD) or Mild Cognitive Impairment (MCI), have a reliable support person or caregiver willing to participate
  

Facial Expressions Study (17-0599)

• Investigator: Peter Pressman, MD
• Purpose: to understand how the brain makes different facial expressions using high speed videography, learn more about how neurological disorders may impact a person’s facial movements and expressions, and develop the groundwork for a diagnostic tool that would detect differences between a person’s facial movements/expressions and their emotions.
• Timeline: one study visit that will last approximately one hour.
• CUACC Website: click here
• Key Eligibility Criteria: age: 18-75 years old, diagnosis: mild cognitive impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder, are right handed.

SESAD (19-2727) 

• Investigator: Peter Pressman, MD
• Purpose: to learn more about the safety and effectiveness of a drug called sargramostim for improving cognitive function and memory in people with Alzheimer’s disease.
• Intervention: if determined to be eligible during screening, you will be assigned to one of two arms of the study: 1) receives study medication; 2) receives placebo (a pill or a liquid that looks like medicine but is not real).
  
• Timeline: after initial screenings at the CU Anschutz campus in Aurora, CO, participants will be able to have weekly home nursing visits. Occasional visits to campus during the study will be required for procedures that cannot be done at home. Including screening and follow-up, study participation last up to 9-1/2 months with up to 55 visits.
  • Screening period will last up to 8 weeks
  • Treatment period will last 24 weeks
  • Follow-up visit occurs 45 days after end of treatment
• Compensation: study related care and medication at no cost.
• Study Flyer: https://www.ucdenver.edu/docs/librariesprovider61/clinical-research-pdfs/sargramostim-ad-13jun2023-approved.pdf
• ClinicalTrials.gov Identifier: NCT04902703
• Key Eligibility Criteria: age: between 60-80 years old, diagnosis: mild-to-moderate Alzheimer’s disease (AD), be willing and able to have a lumbar puncture (spinal tap) and twice weekly blood draws, not have a first degree relative diagnosed with AD before 55 years of age, be willing and able to have an MRI, have a study partner willing to give daily injections after training.

Linda Crnic Institute for Down Syndrome Research Studies

ALLFTD (21-2833)

• Investigator:  Peter Pressman, MD
• Purpose: the ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study aims to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohorts longitudinally and informing clinical trial design (Biofluid-Focused and Longitudinal arms available).
• ClinicalTrials.gov Identifier: NCT04363684

• ALLFTD Biofluid Timeline: one-time visit with questionnaires, neurological exam, blood drawn, and optional lumbar puncture.
• Biofluid Key Eligibility Criteria: age: 18+ years old, diagnosis: FTLD syndrome like bvFTD, bvFTD with ALS, PPA, PSP, or CBD.

• ALLFTD Longitudinal Timeline: annual visit to the clinic, each lasting 2–3 days, with questionnaires, thinking and memory questions, neurological exam, blood drawn, and an MRI.
  
• Longitudinal Key Eligibility Criteria: age: 18+ years old, diagnosis: FTLD syndrome like bvFTD, bvFTD with ALS, PPA, PSP, or CBD, OR are from a family with a mutation in a gene known tocause FTLD (such as C9orf72, MAPT, and GRN) OR have a significant family history of FTLD suggesting a familial genetic mutation.
  

Conversational Speech Analysis (CSA) Study (18-0456)

• Investigator: Peter Pressman, MD
• Purpose: to learn more about how speech changes over time in adult populations, understand how those changes reflect changes in cognition, and develop new ways of detecting MCI and dementia using everyday speech.
• Timeline: two study visits, one year apart.
• Study flyer: click here
• Key Eligibility Criteria: age: 40-95 years old, diagnosis: mild cognitive impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder.

Facial Expressions Study (17-0599)

• Investigator: Peter Pressman, MD
• Purpose: to understand how the brain makes different facial expressions using high speed videography, learn more about how neurological disorders may impact a person’s facial movements and expressions, and develop the groundwork for a diagnostic tool that would detect differences between a person’s facial movements/expressions and their emotions.
• Timeline: one study visit that will last approximately one hour.
• CUACC Website: click here
• Key Eligibility Criteria: age: 18-75 years old, diagnosis: mild cognitive impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder, are right handed.

Facial Expressions Study (17-0599)

• Investigator: Peter Pressman, MD
• Purpose: to understand how the brain makes different facial expressions using high speed videography, learn more about how neurological disorders may impact a person’s facial movements and expressions, and develop the groundwork for a diagnostic tool that would detect differences between a person’s facial movements/expressions and their emotions.
• Timeline: one study visit that will last approximately one hour.
• CUACC Website: click here
• Key Eligibility Criteria: age: 18-75 years old, diagnosis: Mild Cognitive Impairment (MCI) or dementia or have NOT been diagnosed with a memory disorder, are right handed.

SHIMMER (22-0669)

• Investigator: Samantha Holden, MD
• Purpose: to learn about the safety of CT1812 and how well your body tolerates a once-a-day dose of CT1812. The study will also test how well CT1812 will treat mild to moderate dementia with Lewy Bodies (DLB).
• Intervention: low dose of CT1812 (33% chance), high dose of CT1812 (33% chance) or placebo (33% chance).
• Timeline: 12 in-person study visits over 210 days.
• Clinicaltrials.gov: NCT05225415 
• Key Eligibility Criteria: age: 50-85 years old, diagnosis: dementia with Lewy Bodies, have a reliable support person or caregiver willing to participate, willingness to undergo 2 lumbar punctures
  

Conversational Speech Analysis (CSA) Study (18-0456)

• Investigator: Peter Pressman, MD
• Purpose: to learn more about how speech changes over time in adult populations, understand how those changes reflect changes in cognition, and develop new ways of detecting MCI and dementia using everyday speech.
• Timeline: two study visits, one year apart.
• Study flyer: click here
• Key Eligibility Criteria: age: 40-95 years old, diagnosis: mild cognitive impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder.
  

ENVISION (22-0776)

• Investigator: Victoria Pelak, MD
• Purpose: to look at whether aducanumab (ADUHELM™, also known as BIIB037, the study drug) can help slow the development of AD symptoms in people with early AD.
• Intervention: BIIB037 (66% chance) or placebo (33% chance).
• Timeline: up to 39 in-person study visits over 130 weeks.
• Clinicaltrials.gov: NCT05310071 
• Key Eligibility Criteria: age: 60-85 years old, diagnosis: mild Alzheimer’s Disease (AD) or Mild Cognitive Impairment (MCI), have a reliable support person or caregiver willing to participate

Facial Expressions Study (17-0599)

• Investigator: Peter Pressman, MD
• Purpose: to understand how the brain makes different facial expressions using high speed videography, learn more about how neurological disorders may impact a person’s facial movements and expressions, and develop the groundwork for a diagnostic tool that would detect differences between a person’s facial movements/expressions and their emotions.
• Timeline: one study visit that will last approximately one hour.
• CUACC Website: click here
• Key Eligibility Criteria: age: 18-75 years old, diagnosis: mild cognitive impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder, are right handed.